Insider Selling: Sionna Therapeutics (NASDAQ:SION) Director Sells 59,767 Shares of Stock

Sionna Therapeutics, Inc. (NASDAQ:SION) Director Orbimed Advisors Llc sold 59,767 shares of the stock in a transaction on Friday, May 8th. The stock was sold at an average price of $44.58, for a total value of $2,664,412.86. Following the transaction, the director owned 2,856,461 shares of the company’s stock, valued at approximately $127,341,031.38. This represents a 2.05% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Orbimed Advisors Llc also recently made the following trade(s):

• On Monday, May 11th, Orbimed Advisors Llc sold 184,639 shares of Sionna Therapeutics stock. The stock was sold at an average price of $46.22, for a total value of $8,534,014.58.
• On Thursday, May 7th, Orbimed Advisors Llc sold 48,546 shares of Sionna Therapeutics stock. The stock was sold at an average price of $44.61, for a total value of $2,165,637.06.
• On Saturday, April 18th, Orbimed Advisors Llc sold 2,948 shares of Sionna Therapeutics stock. The stock was sold at an average price of $44.52, for a total value of $131,244.96.
• On Friday, April 17th, Orbimed Advisors Llc sold 52,397 shares of Sionna Therapeutics stock. The shares were sold at an average price of $44.68, for a total value of $2,341,097.96.
• On Thursday, April 16th, Orbimed Advisors Llc sold 226,906 shares of Sionna Therapeutics stock. The shares were sold at an average price of $45.34, for a total value of $10,287,918.04.
• On Wednesday, April 15th, Orbimed Advisors Llc sold 235,863 shares of Sionna Therapeutics stock. The shares were sold at an average price of $44.64, for a total value of $10,528,924.32.
• On Tuesday, April 14th, Orbimed Advisors Llc sold 47,814 shares of Sionna Therapeutics stock. The shares were sold at an average price of $44.51, for a total value of $2,128,201.14.

Sionna Therapeutics Trading Up 3.9%

Sionna Therapeutics stock traded up $1.72 during midday trading on Monday, reaching $45.95. 670,726 shares of the stock traded hands, compared to its average volume of 344,329. The company has a 50-day simple moving average of $38.55 and a two-hundred day simple moving average of $39.36. Sionna Therapeutics, Inc. has a 12-month low of $11.77 and a 12-month high of $48.45. The firm has a market cap of $2.07 billion, a PE ratio of -23.56 and a beta of 1.35.

Sionna Therapeutics (NASDAQ:SION) last announced its earnings results on Monday, March 2nd. The company reported ($0.46) EPS for the quarter, beating analysts’ consensus estimates of ($0.61) by $0.15. Equities research analysts anticipate that Sionna Therapeutics, Inc. will post -2.32 earnings per share for the current year.

Institutional Investors Weigh In On Sionna Therapeutics

Several hedge funds and other institutional investors have recently made changes to their positions in the business. AlphaCentric Advisors LLC raised its position in shares of Sionna Therapeutics by 77.1% during the 1st quarter. AlphaCentric Advisors LLC now owns 4,818 shares of the company’s stock worth $193,000 after acquiring an additional 2,098 shares in the last quarter. Jennison Associates LLC raised its position in shares of Sionna Therapeutics by 30.1% during the 1st quarter. Jennison Associates LLC now owns 1,451,220 shares of the company’s stock worth $58,179,000 after acquiring an additional 335,942 shares in the last quarter. Candriam S.C.A. acquired a new stake in shares of Sionna Therapeutics during the 1st quarter worth about $9,494,000. Strs Ohio acquired a new stake in shares of Sionna Therapeutics during the 1st quarter worth about $116,000. Finally, Invesco Ltd. acquired a new stake in shares of Sionna Therapeutics during the 4th quarter worth about $4,573,000.

Analyst Ratings Changes

SION has been the subject of several recent research reports. JonesTrading lifted their price objective on Sionna Therapeutics from $52.00 to $63.00 and gave the company a “buy” rating in a research note on Tuesday, April 28th. Guggenheim lifted their price objective on Sionna Therapeutics from $45.00 to $50.00 and gave the company a “buy” rating in a research note on Monday, March 2nd. Lifesci Capital upgraded Sionna Therapeutics to a “strong-buy” rating in a research note on Wednesday, February 25th. Weiss Ratings reiterated a “sell (d-)” rating on shares of Sionna Therapeutics in a research note on Friday. Finally, UBS Group reiterated a “buy” rating on shares of Sionna Therapeutics in a research note on Monday, March 2nd. Three investment analysts have rated the stock with a Strong Buy rating, six have given a Buy rating and two have given a Sell rating to the stock. According to data from MarketBeat, Sionna Therapeutics has an average rating of “Moderate Buy” and an average price target of $53.00.

About Sionna Therapeutics

Sionna Therapeutics is a clinical-stage biotechnology company dedicated to developing next-generation RNA therapeutics for oncology and immunology indications. Leveraging proprietary lipid nanoparticle and coacervate delivery technologies, the company aims to overcome key challenges associated with stability, targeting and immune activation that have historically limited the clinical performance of mRNA-based medicines. Its strategic focus spans both solid tumors and hematological malignancies, as well as selected autoimmune disorders, reflecting a broad ambition to harness the power of messenger RNA in diverse therapeutic areas.

At the heart of Sionna’s approach is a platform that combines optimized ionizable lipids with bespoke surface chemistries to enhance payload delivery, intracellular release and endosomal escape.